Passion and purpose to transform patient journeys in anxiety and depression.

Jaakko Lappalainen, M.D., Ph.D. brings decades of experience in clinical practice, early- and late-stage clinical development, and academic research. Prior to joining Vistagen, Dr. Lappalainen served as Chief, Addiction Psychiatry at Crozer Health where he was responsible for providing medical leadership for a large addiction treatment program. Previously, Dr. Lappalainen held various medical leadership roles at AstraZeneca, Marinus Pharmaceuticals, and Premier Research, a leading clinical research and development organization (CRO). He has extensive experience in the planning and execution of clinical trials across Phases I-III, including the studies leading to regulatory approval of Movantik® by the U.S. Food and Drug Administration. Earlier in his career, Dr. Lappalainen was Assistant Professor of Psychiatry at Yale University School of Medicine. Dr. Lappalainen received his Ph.D. and M.D. from the University of Turku, School of Medicine in Finland.